ALKS Key Statistics, Chart & Performance
The current stock price of ALKS is 34.91 USD. In the past month the price increased by 17.94%. In the past year, price increased by 10.58%.
ALKS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ALKS. When comparing the yearly performance of all stocks, ALKS turns out to be only a medium performer in the overall market: it outperformed 60.68% of all stocks.
ALKS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALKS. ALKS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
ALKS Financial Highlights
Over the last trailing twelve months ALKS reported a non-GAAP Earnings per Share(EPS) of 2.48. The EPS increased by 19.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.3% | ||
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| Debt/Equity | 0 |
ALKS Forecast & Estimates
23 analysts have analysed ALKS and the average price target is 44.56 USD. This implies a price increase of 27.65% is expected in the next year compared to the current price of 34.91.
For the next year, analysts expect an EPS growth of -48.21% and a revenue growth -2.47% for ALKS
ALKS Ownership
ALKS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALKS
Company Profile
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 1,800 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Company Info
ALKERMES PLC
Connaught House, 1 Burlington Road, Dublin 4
DUBLIN DUBLIN DUBLIN 4 IE
CEO: Richard F. Pops
Employees: 1800
Phone: 35317728000
ALKERMES PLC / ALKS FAQ
What does ALKS do?
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 1,800 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
What is the stock price of ALKERMES PLC today?
The current stock price of ALKS is 34.91 USD. The price increased by 4.05% in the last trading session.
What is the dividend status of ALKERMES PLC?
ALKS does not pay a dividend.
How is the ChartMill rating for ALKERMES PLC?
ALKS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is ALKS stock listed?
ALKS stock is listed on the Nasdaq exchange.
Is ALKERMES PLC (ALKS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALKS.